The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study

被引:6
作者
Lev-Ari, Shaked [1 ]
Serzan, Michael [2 ]
Wu, Tianmin [3 ]
Ip, Andrew [4 ,5 ,6 ]
Pascual, Lauren [4 ]
Sinclaire, Brittany [4 ]
Adams, Shari [5 ]
Marafelias, Michael [4 ]
Ayyagari, Lakshmi [4 ]
Gill, Sarvarinder K. [4 ]
Ma, Barbara [7 ]
Zaemes, Jacob P. [1 ]
Della Pia, Alexandra [5 ]
Alaoui, Adil [8 ]
Madhavan, Subha [8 ]
Belouali, Anas [8 ]
Pecora, Andrew [4 ,5 ,6 ]
Ahn, Jaeil [3 ]
Atkins, Michael B. [1 ]
Shah, Neil J. [7 ,9 ]
机构
[1] Georgetown Lombardi Comprehens Canc Ctr, Dept Oncol, Georgetown, WA USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[3] Georgetown Univ, Med Ctr, Dept Biostat Bioinformat & Biomath, Washington, DC 20007 USA
[4] Hackensack Meridian Hlth, John Theurer Canc Ctr, Hackensack, NJ USA
[5] Hackensack Meridian Hlth, Dept Oncol, Hackensack, NJ USA
[6] Hackensack Meridian Sch Med, Nutley, NJ USA
[7] Weill Cornell Med Ctr, Dept Med, New York, NY USA
[8] Georgetown Univ, Innovat Ctr Biomed Informat, Washington, DC USA
[9] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
关键词
immune checkpoint inhibitors; immune-related adverse events; immunosuppressive agents; melanoma; nivolumab; pembrolizumab; steroids; ADVERSE EVENTS; NIVOLUMAB; IPILIMUMAB; SURVIVAL;
D O I
10.1002/cncr.34742
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundImmune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) are often managed via immunosuppressive agents (ISAs); however, their impact on ICI efficacy is not well studied. The impact of the use of ISAs on ICI efficacy in patients with advanced melanoma was therefore investigated. MethodsThis is a real-world, multicenter, retrospective cohort study of patients with advanced melanoma who received ICIs (n = 370). Overall survival (OS) and time to treatment failure (TTF) from the time of ICI initiation were compared among patients in subgroups of interest by unadjusted and 12-week landmark sensitivity-adjusted analyses. The association of irAEs and their management with OS and TTF were evaluated using univariate and multivariable Cox proportional hazards regression models. ResultsOverall, irAEs of any grade and of grade >= 3 occurred in 57% and 23% of patients, respectively. Thirty-seven percent of patients received steroids, and 3% received other ISAs. Median OS was longest among patients receiving both (not reached [NR]), shorter among those receiving only systemic steroids (SSs) (84.2 months; 95% CI, 40.2 months to NR), and shortest among those who did not experience irAEs (10.3 months; 95% CI, 6-20.1 months) (p < .001). Longer OS was significantly associated with the occurrence of irAEs and the use of SSs with or without ISAs upon multivariable-adjusted analysis (p < .001). Similar results were noted with anti-programmed death 1 (PD-1) monotherapy and combination anti-PD-1 plus anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy, and with 12-week landmark sensitivity analysis (p = .01). ConclusionsThese findings in patients with melanoma who were treated with ICIs suggest that the use of SSs or ISAs for the management of irAEs is not associated with inferior disease outcomes, which supports the use of these agents when necessary.
引用
收藏
页码:1885 / 1894
页数:10
相关论文
共 23 条
  • [1] Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
    Arbour, Kathryn C.
    Mezquita, Laura
    Long, Niamh
    Rizvi, Hira
    Auclin, Edouard
    Ni, Andy
    Martinez-Bernal, Gala
    Ferrara, Roberto
    Lai, W. Victoria
    Hendriks, Lizza E. L.
    Sabari, Joshua K.
    Caramella, Caroline
    Plodkowski, Andrew J.
    Halpenny, Darragh
    Chaft, Jamie E.
    Planchard, David
    Riely, Gregory J.
    Besse, Benjamin
    Hellmann, Matthew D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) : 2872 - +
  • [2] Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy
    Bai, Xue
    Hu, Jiani
    Warner, Allison Betof
    Quach, Henry T.
    Cann, Christopher G.
    Zhang, Michael Z.
    Si, Lu
    Tang, Bixia
    Cui, Chuanliang
    Yang, Xiaoling
    Wei, Xiaoting
    Pallan, Lalit
    Harvey, Catriona
    Manos, Michael P.
    Ouyang, Olivia
    Kim, Michelle S.
    Kasumova, Gyulnara
    Cohen, Justine V.
    Lawrence, Donald P.
    Freedman, Christine
    Fadden, Riley M.
    Rubin, Krista M.
    Sharova, Tatyana
    Frederick, Dennie T.
    Flaherty, Keith T.
    Rahma, Osama E.
    Long, Georgina V.
    Menzies, Alexander M.
    Guo, Jun
    Shoushtari, Alexander N.
    Johnson, Douglas B.
    Sullivan, Ryan J.
    Boland, Genevieve M.
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (21) : 5993 - 6000
  • [3] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
    Brahmer, Julie R.
    Abu-Sbeih, Hamzah
    Ascierto, Paolo Antonio
    Brufsky, Jill
    Cappelli, Laura C.
    Cortazar, Frank B.
    Gerber, David E.
    Hamad, Lamya
    Hansen, Eric
    Johnson, Douglas B.
    Lacouture, Mario E.
    Masters, Gregory A.
    Naidoo, Jarushka
    Nanni, Michele
    Perales, Miguel-Angel
    Puzanov, Igor
    Santomasso, Bianca D.
    Shanbhag, Satish P.
    Sharma, Rajeev
    Skondra, Dimitra
    Sosman, Jeffrey A.
    Turner, Michelle
    Ernstoff, Marc S.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (06)
  • [4] Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma
    Drakaki, Alexandra
    Dhillon, Preet K.
    Wakelee, Heather
    Chui, Stephen Y.
    Shim, Jinjoo
    Kent, Matthew
    Degaonkar, Viraj
    Hoang, Tien
    McNally, Virginia
    Luhn, Patricia
    Gutzmer, Ralf
    [J]. ONCOIMMUNOLOGY, 2020, 9 (01):
  • [5] Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo A Secondary Analysis of a Randomized Clinical Trial
    Eggermont, Alexander M. M.
    Kicinski, Michal
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina V.
    Atkinson, Victoria
    Dalle, Stephane
    Haydon, Andrew
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Koornstra, Rutger
    Hernandez-Aya, Leonel
    Di Giacomo, Anna Maria
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    Lorigan, Paul C.
    Krepler, Clemens
    Ibrahim, Nageatte
    Marreaud, Sandrine
    van Akkooi, Alexander
    Robert, Caroline
    Suciu, Stefan
    [J]. JAMA ONCOLOGY, 2020, 6 (04) : 519 - 527
  • [6] Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
    Eggermont, Alexander M. M.
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina, V
    Atkinson, Victoria
    Dalle, Stephane
    Haydon, Andrew
    Lichinitser, Mikhail
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Koornstra, Rutger
    Hernandez-Aya, Leonel
    Maio, Michele
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    Lorigan, Paul
    Ibrahim, Nageatte
    Marreaud, Sandrine
    van Akkooi, Alexander C. J.
    Suciu, Stefan
    Robert, Caroline
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (19) : 1789 - 1801
  • [7] Moving towards personalized treatments of immune-related adverse events
    Esfahani, Khashayar
    Elkrief, Arielle
    Calabrese, Cassandra
    Lapointe, Rejean
    Hudson, Marie
    Routy, Bertrand
    Miller, Wilson H., Jr.
    Calabrese, Leonard
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (08) : 504 - 515
  • [8] Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
    Horvat, Troy Z.
    Adel, Nelly G.
    Thu-Oanh Dung
    Momtaz, Parisa
    Postow, Michael A.
    Callahan, Margaret K.
    Carvajal, Richard D.
    Dickson, Mark A.
    D'Angelo, Sandra P.
    Woo, Kaitlin M.
    Panageas, Katherine S.
    Wolchok, Jedd D.
    Chapman, Paul B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28) : 3193 - +
  • [9] Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors-A systematic review and meta-analysis
    Hussaini, Syed
    Chehade, Rania
    Boldt, Ronald Gabriel
    Raphael, Jacques
    Blanchette, Phillip
    Vareki, Saman Maleki
    Fernandes, Ricardo
    [J]. CANCER TREATMENT REVIEWS, 2021, 92
  • [10] Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
    Larkin, J.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Grob, J-J
    Rutkowski, P.
    Lao, C. D.
    Cowey, C. L.
    Schadendorf, D.
    Wagstaff, J.
    Dummer, R.
    Ferrucci, P. F.
    Smylie, M.
    Hogg, D.
    Hill, A.
    Marquez-Rodas, I.
    Haanen, J.
    Guidoboni, M.
    Maio, M.
    Schoffski, P.
    Carlino, M. S.
    Lebbe, C.
    McArthur, G.
    Ascierto, P. A.
    Daniels, G. A.
    Long, G. V.
    Bastholt, L.
    Rizzo, J. I.
    Balogh, A.
    Moshyk, A.
    Hodi, F. S.
    Wolchok, J. D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (16) : 1535 - 1546